Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.

Core Insights - Microbot Medical Inc. has announced the commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, marking a significant milestone in the introduction of single-use robotic systems for peripheral endovascular procedures [1][2] - The Limited Market Release (LMR) will focus on high procedure volume regions to gather real-world insights and prepare for a Full Market Release (FMR) expected at the Society of Interventional Radiology meeting in April 2026 [1][2] Company Developments - The company has established a core commercial team and secured a third-party logistics partner to support the LMR of LIBERTY® [2] - Positive feedback from physicians and hospital administrators has validated the decision to proceed with the limited market release [1][2] Product Overview - LIBERTY® is the first FDA cleared single-use, remotely operated robotic system designed for precision, efficiency, and safety in endovascular procedures [3] - The product is backed by a strong intellectual property portfolio and a commitment to innovation, positioning Microbot Medical as a leader in the endovascular care market [3]